울트라제닉스제약(주)
GB ˙ LSE ˙ US90400D1081
US$21.92 ↓ -1.30 (-5.60%)
2026-06-05
주가
SecurityGB:0LIF / Ultragenyx Pharmaceutical Inc.
InstitutionBarclays Plc
Latest Disclosed Ownership359,148 shares
Latest Disclosed Value $ 8,260,404
Barclays Plc ownership in 0LIF / Ultragenyx Pharmaceutical Inc.

On February 13, 2026 - Barclays Plc filed a 13F-HR form disclosing ownership of 359,148 shares of Ultragenyx Pharmaceutical Inc. (GB:0LIF) valued at $8,086,505 USD as of December 31, 2025. The entity filed a previous 13F-HR/A on March 31, 2026 disclosing 425,351 shares of Ultragenyx Pharmaceutical Inc.. This represents a change in shares of -15.56% during the quarter. The current value of the position is $7,872,488 USD.

Barclays Plc has a history of taking positions in derivatives of the underlying security (0LIF) in the form of stock options. The firm currently holds call options representing 200,000 of underlying shares valued at $4,600,000 USD and put options representing 0 of underlying shares valued at $0 USD .

Note: prior versions of this page mistakenly stated that the share values represented the number of options, not the number of underlying shares. For more information on the data backing these reports, please see the SEC document Frequently Asked Questions About Form 13F.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Institutional Put/Call Ratios
(Premium Subscription Required)

In addition to reporting standard equity and debt issues, institutions with more than 100MM assets under management must also disclose their put and call option holdings. Since put options generally indicate negative sentiment, and call options indicate positive sentiment, we can get a sense of the overall institutional sentiment by plotting the ratio of puts to calls. The chart to the right plots the historical put/call ratio for this instrument.

Using Put/Call Ratio as an indicator of investor sentiment overcomes one of the key deficiencies of using total institutional ownership, which is that a significant amount of assets under management are invested passively to track indices. Passively-managed funds do not typically buy options, so the put/call ratio indicator more closely tracks the sentiment of actively-managed funds.

GB:0LIF / Ultragenyx Pharmaceutical Inc. Historical Put/Call Ratio
Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2026-02-13 2025-12-31 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 359,148 -66,203 -15.56 8,260 -35.44 0.0020
2026-03-31 2025-09-30 13F/A-3 ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 425,351 246,740 138.14 12,795 97.01 0.0028
2026-03-19 2025-09-30 13F/A-2 ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 79,546 -99,065 4,419 0.0012
2025-11-12 2025-09-30 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 425,351 246,740 12,795 0.0028
2026-02-27 2025-06-30 13F/A-2 ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 178,611 35,730 25.01 6,494 25.54 0.0015
2025-08-14 2025-06-30 13F/A-1 ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 178,611 35,730 6 0.0015
2025-08-13 2025-06-30 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 178,611 35,730 6 0.0005
2026-03-17 2025-03-31 13F/A-1 ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 142,881 -63,227 -30.68 5,174 -40.33 0.0015
2025-05-15 2025-03-31 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 142,881 -63,227 5 0.0015
2026-03-19 2024-12-31 13F/A-1 ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 206,108 126,562 159.11 8,671 96.24 0.0024
2025-02-13 2024-12-31 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 206,108 126,562 9 0.0024
2026-03-31 2024-09-30 13F/A-2 ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 79,546 16,633 26.44 4,419 70.91 0.0012
2024-11-19 2024-09-30 13F/A-1 ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 79,546 16,633 4 0.0012
2024-11-15 2024-09-30 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 79,546 16,633 4 0.0004
2026-03-23 2024-06-30 13F/A-1 ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 62,913 -55,860 -47.03 2,586 -53.38 0.0008
2024-08-14 2024-06-30 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 62,913 -55,860 3 0.0008
2026-03-24 2024-03-31 13F/A-1 ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 118,773 -47,969 -28.77 5,546 -30.45 0.0019
2024-05-15 2024-03-31 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 118,773 -47,969 6 0.0019
2026-03-25 2023-12-31 13F/A-1 ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 166,742 46,049 38.15 7,974 85.33 0.0029
2024-02-15 2023-12-31 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 166,742 46,049 8 0.0029
2026-03-26 2023-09-30 13F/A-1 ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 120,693 18,552 18.16 4,303 -8.68 0.0027
2023-11-07 2023-09-30 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 120,693 18,552 4 0.0027
2026-03-30 2023-06-30 13F/A-2 ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 102,141 10,474 11.43 4,712 28.19 0.0030
2023-09-20 2023-06-30 13F/A-1 ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 102,141 10,474 5 0.0030
2023-08-03 2023-06-30 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 102,141 10,474 5 0.0030
2026-03-30 2023-03-31 13F/A-1 ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 91,667 -32,920 -26.42 3,676 -36.33 0.0017
2023-05-04 2023-03-31 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 91,667 -32,920 4 0.0017
2026-03-30 2022-12-31 13F/A-1 ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 124,587 8,997 7.78 5,772 20.55 0.0026
2023-02-13 2022-12-31 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 124,587 8,997 6 0.0026
2022-11-03 2022-09-30 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 115,590 95,515 475.79 4,788 299.67 0.0052
2022-08-12 2022-06-30 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 20,075 473 2.41 1,198 -15.81 0.0007
2022-05-16 2022-03-31 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 19,602 -3,828 -16.34 1,423 -27.77 0.0011
2022-02-23 2021-12-31 13F/A-1 ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 23,430 18,715 396.92 1,970 363.53 0.0007
2022-02-14 2021-12-31 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 23,430 18,715 1,970 0.0002
2021-11-09 2021-09-30 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 4,715 -19,665 -80.66 425 -81.73 0.0002
2021-08-13 2021-06-30 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 24,380 -47,296 -65.99 2,326 -71.50 0.0011
2021-05-13 2021-03-31 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 71,676 48,152 204.69 8,161 150.57 0.0044
2021-02-11 2020-12-31 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 23,524 -74,107 -75.91 3,257 -59.41 0.0017
2020-11-12 2020-09-30 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 97,631 63,161 183.23 8,025 197.66 0.0048
2020-08-12 2020-06-30 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 34,470 -117,302 -77.29 2,696 -60.01 0.0021
2020-05-13 2020-03-31 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 151,772 38,561 34.06 6,742 39.44 0.0053
2020-02-10 2019-12-31 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 113,211 86,164 318.57 4,835 318.25 0.0027
2019-11-15 2019-09-30 13F/A-1 ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 27,047 -8,287 -23.45 1,156 -48.46 0.0007
2019-11-14 2019-09-30 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 27,047 -8,287 1,156 267.2685
2019-08-14 2019-06-30 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 35,334 11,670 49.32 2,243 36.60 0.0014
2019-05-15 2019-03-31 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 23,664 17,400 277.78 1,642 501.47 0.0011
2019-02-14 2018-12-31 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 6,264 -20,985 -77.01 273 -86.87 0.0002
2018-11-14 2018-09-30 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 27,249 16,246 147.65 2,080 145.86 0.0014
2018-08-14 2018-06-30 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 11,003 -602 -5.19 846 42.91 0.0007
2018-05-15 2018-03-31 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 11,605 2,622 29.19 592 42.31 0.0005
2018-02-14 2017-12-31 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 8,983 5,594 165.06 416 131.11 0.0003
2017-11-14 2017-09-30 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 3,389 1,747 106.39 180 76.47 0.0002
2017-08-14 2017-06-30 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 1,642 -21,943 -93.04 102 -93.62 0.0001
2017-05-15 2017-03-31 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 23,585 18,282 344.75 1,598 328.42 0.0017
2017-02-14 2016-12-31 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 5,303 -29,740 -84.87 373 -84.99 0.0004
2016-11-14 2016-09-30 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 35,043 32,566 1,314.74 2,485 1,953.72 0.0028
2016-08-12 2016-06-30 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 2,477 -2,562 -50.84 121 -61.95 0.0002
2016-05-16 2016-03-31 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 5,039 3,542 236.61 318 90.42 0.0005
2016-02-12 2015-12-31 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 1,497 -10,365 -87.38 167 -85.34 0.0002
2015-11-13 2015-09-30 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 11,862 -8,883 -42.82 1,139 -46.17 0.0014
2015-08-14 2015-06-30 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 20,745 20,010 2,722.45 2,116 4,602.22 0.0024
2015-05-19 2015-03-31 13F/A-1 ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 735 65 9.70 45 55.17 0.0001
2015-05-14 2015-03-31 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 735 45
2015-02-13 2014-12-31 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 670 426 174.59 29 107.14 0.0000
2014-11-14 2014-09-30 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 244 125 105.04 14 133.33 0.0000
2014-08-14 2014-06-30 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 119 -62 -34.25 6 -33.33 0.0000
2014-05-15 2014-03-31 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 181 181 9 0.0000
Disclosed Call Options
File
Date
Effective
Date
Form Security Class ID Opt Avg Share
Price
Shares ΔShares
(%)
Value
(x1000)
ΔValue
(%)
Prior Allocation
(%)
Allocation
(%)
ΔAllocation
(%)
Cost Basis
(x1000)
Profit
(x1000)
Return
(%)
2026-02-13 2025-12-31 13F ULTRAGENYX PHARMACEUTICAL IN OPT Call 200,000 0.00 4,600 -23.54 n/a n/a n/a
2026-03-31 2025-09-30 13F/A ULTRAGENYX PHARMACEUTICAL IN OPT Call 200,000 -48.93 6,016 -57.75 n/a n/a n/a
2025-11-12 2025-09-30 13F ULTRAGENYX PHARMACEUTICAL IN OPT Call 200,000 6,016 n/a n/a n/a
2025-08-14 2025-06-30 13F/A ULTRAGENYX PHARMACEUTICAL IN OPT Call 391,600 14 n/a n/a n/a
2026-02-27 2025-06-30 13F/A ULTRAGENYX PHARMACEUTICAL IN OPT Call 391,600 881.45 14,239 886.01 n/a n/a n/a
2026-03-17 2025-03-31 13F/A ULTRAGENYX PHARMACEUTICAL IN OPT Call 39,900 1,445 n/a n/a n/a
2025-05-15 2025-03-31 13F ULTRAGENYX PHARMACEUTICAL IN OPT Call 39,900 1 n/a n/a n/a
2024-11-19 2024-09-30 13F/A ULTRAGENYX PHARMACEUTICAL IN OPT Call 0 0 n/a n/a n/a
2026-03-31 2024-09-30 13F/A ULTRAGENYX PHARMACEUTICAL IN OPT Call 0 -100.00 0 -100.00 n/a n/a n/a
2024-11-15 2024-09-30 13F ULTRAGENYX PHARMACEUTICAL IN OPT Call 0 0 n/a n/a n/a
2026-03-23 2024-06-30 13F/A ULTRAGENYX PHARMACEUTICAL IN OPT Call 174,000 480.00 7,151 410.79 n/a n/a n/a
2024-08-14 2024-06-30 13F ULTRAGENYX PHARMACEUTICAL IN OPT Call 174,000 7 n/a n/a n/a
2026-03-24 2024-03-31 13F/A ULTRAGENYX PHARMACEUTICAL IN OPT Call 30,000 0.00 1,401 -2.37 n/a n/a n/a
2024-05-15 2024-03-31 13F ULTRAGENYX PHARMACEUTICAL IN OPT Call 30,000 1 n/a n/a n/a
2026-03-25 2023-12-31 13F/A ULTRAGENYX PHARMACEUTICAL IN OPT Call 30,000 1,435 n/a n/a n/a
2024-02-15 2023-12-31 13F ULTRAGENYX PHARMACEUTICAL IN OPT Call 30,000 1 n/a n/a n/a
2019-08-14 2019-06-30 13F ULTRAGENYX PHARMACEUTICAL IN OPT Call 0 -100.00 0 -100.00 n/a n/a n/a
2019-05-15 2019-03-31 13F ULTRAGENYX PHARMACEUTICAL IN OPT Call 50,000 3,468 n/a n/a n/a
2019-02-14 2018-12-31 13F ULTRAGENYX PHARMACEUTICAL IN OPT Call 0 -100.00 0 -100.00 n/a n/a n/a
2018-11-14 2018-09-30 13F ULTRAGENYX PHARMACEUTICAL IN OPT Call 700 600.00 53 562.50 n/a n/a n/a
2018-08-14 2018-06-30 13F ULTRAGENYX PHARMACEUTICAL IN OPT Call 100 0.00 8 60.00 n/a n/a n/a
2018-05-15 2018-03-31 13F ULTRAGENYX PHARMACEUTICAL IN OPT Call 100 0.00 5 0.00 n/a n/a n/a
2018-02-14 2017-12-31 13F ULTRAGENYX PHARMACEUTICAL IN OPT Call 100 5 n/a n/a n/a
2017-11-14 2017-09-30 13F ULTRAGENYX PHARMACEUTICAL IN OPT Call 0 -100.00 0 -100.00 n/a n/a n/a
2017-08-14 2017-06-30 13F ULTRAGENYX PHARMACEUTICAL IN OPT Call 600 -93.94 37 -94.49 n/a n/a n/a
2017-05-15 2017-03-31 13F ULTRAGENYX PHARMACEUTICAL IN OPT Call 9,900 890.00 671 858.57 n/a n/a n/a
2017-02-14 2016-12-31 13F ULTRAGENYX PHARMACEUTICAL IN OPT Call 1,000 70 n/a n/a n/a
Disclosed Put Options
File
Date
Effective
Date
Form Security Class ID Opt Avg Share Price Shares ΔShares
(%)
Value
(x1000)
ΔValue
(%)
Prior Allocation
(%)
Allocation
(%)
ΔAllocation
(%)
Cost Basis
(x1000)
Profit
(x1000)
Return
(%)
2025-08-14 2025-06-30 13F/A ULTRAGENYX PHARMACEUTICAL IN OPT Put 0 0 n/a n/a n/a
2026-02-27 2025-06-30 13F/A ULTRAGENYX PHARMACEUTICAL IN OPT Put 0 -100.00 0 -100.00 n/a n/a n/a
2025-08-13 2025-06-30 13F ULTRAGENYX PHARMACEUTICAL IN OPT Put 0 0 n/a n/a n/a
2026-03-17 2025-03-31 13F/A ULTRAGENYX PHARMACEUTICAL IN OPT Put 12,500 453 n/a n/a n/a
2025-05-15 2025-03-31 13F ULTRAGENYX PHARMACEUTICAL IN OPT Put 12,500 0 n/a n/a n/a
2026-03-23 2024-06-30 13F/A ULTRAGENYX PHARMACEUTICAL IN OPT Put 0 -100.00 0 -100.00 n/a n/a n/a
2024-08-14 2024-06-30 13F ULTRAGENYX PHARMACEUTICAL IN OPT Put 0 0 n/a n/a n/a
2026-03-24 2024-03-31 13F/A ULTRAGENYX PHARMACEUTICAL IN OPT Put 30,000 0.00 1,401 -2.37 n/a n/a n/a
2024-05-15 2024-03-31 13F ULTRAGENYX PHARMACEUTICAL IN OPT Put 30,000 1 n/a n/a n/a
2026-03-25 2023-12-31 13F/A ULTRAGENYX PHARMACEUTICAL IN OPT Put 30,000 1,435 n/a n/a n/a
2024-02-15 2023-12-31 13F ULTRAGENYX PHARMACEUTICAL IN OPT Put 30,000 1 n/a n/a n/a
2019-08-14 2019-06-30 13F ULTRAGENYX PHARMACEUTICAL IN OPT Put 0 -100.00 0 -100.00 n/a n/a n/a
2019-05-15 2019-03-31 13F ULTRAGENYX PHARMACEUTICAL IN OPT Put 600 0.00 42 61.54 n/a n/a n/a
2019-02-14 2018-12-31 13F ULTRAGENYX PHARMACEUTICAL IN OPT Put 600 26 n/a n/a n/a
2018-02-14 2017-12-31 13F ULTRAGENYX PHARMACEUTICAL IN OPT Put 0 -100.00 0 -100.00 n/a n/a n/a
2017-11-14 2017-09-30 13F ULTRAGENYX PHARMACEUTICAL IN OPT Put 100 -80.00 5 -83.87 n/a n/a n/a
2017-08-14 2017-06-30 13F ULTRAGENYX PHARMACEUTICAL IN OPT Put 500 0.00 31 -8.82 n/a n/a n/a
2017-05-15 2017-03-31 13F ULTRAGENYX PHARMACEUTICAL IN OPT Put 500 34 n/a n/a n/a
2015-11-13 2015-09-30 13F ULTRAGENYX PHARMACEUTICAL IN OPT Put 0 -100.00 0 -100.00 n/a n/a n/a
2015-08-14 2015-06-30 13F ULTRAGENYX PHARMACEUTICAL IN OPT Put 25,000 2,550 n/a n/a n/a
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.